It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The cell-envelope of Gram-negative bacteria contains endotoxic lipopolysaccharides (LPS) that are recognized by the innate immune system via Toll-Like Receptors (TLRs). The intestinal mucosal symbiont Akkermansia muciniphila is known to confer beneficial effects on the host and has a Gram-negative architecture. Here we show that A. muciniphila LPS lacks the O-polysaccharide repeating unit, with the resulting lipooligosaccharide (LOS) having unprecedented structural and signaling properties. The LOS consists of a complex glycan chain bearing two distinct undeca- and hexadecasaccharide units each containing three 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) residues. The lipid A moiety appears as a mixture of differently phosphorylated and acylated species and carries either linear or branched acyl moieties. Peritoneal injection of the LOS in mice increased higher gene expression of liver TLR2 than TLR4 (100-fold) and induced high IL-10 gene expression. A. muciniphila LOS was found to signal both through TLR4 and TLR2, whereas lipid A only induced TLR2 in a human cell line. We propose that the unique structure of the A. muciniphila LOS allows interaction with TLR2, thus generating an anti-inflammatory response as to compensate for the canonical inflammatory signaling associated with LOS and TLR4, rationalizing its beneficial host interaction.
Here, the authors characterize the structure of the Lipooligosaccharide of the gut symbiont Akkermansia muciniphila showing unique features and TLR4 and TLR2 signaling capacity, which underscore the beneficial properties of this bacterium.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of Naples Federico II, Department of Chemical Sciences, Napoli, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
2 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666); Société des Produits Nestlé S.A., Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland (GRID:grid.419905.0) (ISNI:0000 0001 0066 4948)
3 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666)
4 Université Catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research group, UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); 6, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, avenue Pasteur, Wavre, Belgium (GRID:grid.509491.0)
5 Université Catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research group, UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); 6, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, avenue Pasteur, Wavre, Belgium (GRID:grid.509491.0); Université catholique de Louvain, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)
6 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978)
7 University of Florence, Magnetic Resonance Center (CERM), CIRMMP and Department of Chemistry “Ugo Schiff”, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
8 University of Naples Federico II, Department of Chemical Sciences, Napoli, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); Osaka University, Department of Chemistry, School of Science, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
9 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666); University of Helsinki, Human Microbiome Research Program, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)